New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
10:00 EDTCWH, IDIX, INFY, FDO, SHPG, FASTOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
News For SHPG;INFY;CWH;FDO;IDIX;FAST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 30, 2015
07:39 EDTINFYInfosys partners with Microsoft to offer Finacle on Azure
Subscribe for More Information
07:09 EDTSHPGShire reaffirms 2015 EPS growth outlook of mid-single digits
Shire said, "We've made a strong start to 2015, and remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015. On a Constant Exchange Rate basis we continue to expect product sales growth in the mid-to-high single digits. When excluding INTUNIV, we anticipate low double digit product sales growth on a CER basis. Based on current exchange rates we anticipate low-to-mid single digit product sales growth in 2015, as we expect growth to be held back three to four percentage points by foreign exchange headwinds which particularly impact ELAPRASE, REPLAGAL and VPRIV sales. We expect to see a lower rate of product sales growth through the remainder of 2015 than we've delivered in the first quarter, principally due to stronger comparatives. Royalties and other revenues are expected to increase by 30-40% in 2015, as we include NPS's royalty streams for the first time. Our Non GAAP gross margin is expected to be in line with 2014."
07:08 EDTSHPGShire reports Q1 adjysted EPS $2.84, consensus $2.61
Subscribe for More Information
07:06 EDTSHPGShire appoints Jeff Poulton as CFO
Subscribe for More Information
April 29, 2015
10:00 EDTSHPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:33 EDTSHPGShire initiated with an Outperform at Exane BNP Paribas
Subscribe for More Information
April 27, 2015
10:00 EDTINFYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: 3D Systems (DDD) downgraded to Hold from Buy at Canaccord... Akorn (AKRX) downgraded to Neutral from Overweight at Piper Jaffray... Allegiant Travel (ALGT) downgraded to Fair Value from Buy at CRT Capital... Altera (ALTR) downgraded to Neutral from Outperform at Baird... Amazon.com (AMZN) downgraded on valuation at Argus... American Science & Engineering (ASEI) downgraded to Sell from Fair Value at CRT Capital... Basic Energy (BAS) downgraded to Underperform from Neutral at Macquarie... C.H. Robinson (CHRW) downgraded to Sell from Neutral at UBS... Celladon (CLDN) downgraded to Neutral from Buy at Roth Capital... DST Systems (DST) downgraded to Neutral from Outperform at Credit Suisse... DeVry (DV) downgraded on weaker than expected outlook at Stifel... Eaton Vance (EV) downgraded to Sell from Neutral at Citigroup... Emerge Energy (EMES) downgraded to Hold from Buy at Wunderlich... FMC Technologies (FTI) downgraded to Accumulate from Speculative Buy at Global Hunter... Fibria Celulose (FBR) downgraded to Underweight from Equal Weight at Morgan Stanley... Forum Energy (FET) downgraded to Neutral at Baird... Gulf Island Fabrication (GIFI) downgraded to Hold from Accumulate at Johnson Rice... Hancock Holding (HBHC) downgraded to Hold from Buy at Drexel Hamilton... Hi-Crush Partners (HCLP) downgraded to Hold from Buy at Wunderlich... Houghton Mifflin (HMHC) downgraded to Neutral from Buy at Citigroup (Friday)... Infosys (INFY) downgraded to Hold from Buy at Deutsche Bank... Marvell (MRVL) downgraded to Hold from Buy at Craig-Hallum... Merge Healthcare (MRGE) downgraded to Hold from Buy at Topeka... Oceaneering (OII) downgraded to Neutral from Buy at Goldman... Omega Healthcare (OHI) downgraded at BofA/Merrill... Perrigo (PRGO) downgraded to Neutral from Buy at UBS... Petrobras (PBR) downgraded to Underweight from Equal Weight at Morgan Stanley... Procter & Gamble (PG) downgraded on lack of upside at CLSA... ResMed (RMD) downgraded to Neutral from Buy at Goldman... Seadrill (SDRL) downgraded to Sell from Neutral at Citigroup... Six Flags (SIX) downgraded to Neutral from Buy at Goldman... Stratasys (SSYS) downgraded to Hold at Canaccord... Telecom Italia (TI) downgraded to Neutral from Buy at BofA/Merrill... Twitter (TWTR) downgraded to Neutral from Buy at SunTrust... United Continental (UAL) downgraded to Fair Value from Buy at CRT Capital... Virgin America (VA) downgraded to Sell from Buy at CRT Capital.
07:56 EDTINFYInfosys downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Infosys to Hold saying the company's FY16 revenue growth guidance is "not modest" and its FY20 goals look "aggressive."
07:27 EDTINFYAccenture has made transition to higher level work, says Wells Fargo
Subscribe for More Information
April 24, 2015
10:00 EDTINFYInfosys falls after earnings, levels to watch
Subscribe for More Information
05:34 EDTINFYInfosys sees industry going through 'fundamental and structural transition'
CEO Vishal Sikka commented, "Despite being a challenging quarter, I am encouraged by the early successes in executing our Renew-New strategy, on a foundation of learning."
05:33 EDTINFYInfosys sees FY16 revenue growth of 10%-12% in constant currency terms
Subscribe for More Information
05:32 EDTINFYInfosys board increases dividend pay-out ratio to 50% of post-tax profits
Subscribe for More Information
05:31 EDTINFYInfosys board recommends bonus issue of one equity share for every share held
Subscribe for More Information
05:28 EDTINFYInfosys reports Q4 EPS 44c, consensus 44c
Reports Q4 revenue $2.16B, consensus $2.24B
April 23, 2015
15:01 EDTINFYNotable companies reporting before tomorrow's open
Subscribe for More Information
09:20 EDTSHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
07:07 EDTSHPGEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 20, 2015
14:32 EDTSHPGPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information
10:11 EDTFASTOptions with decreasing implied volatility
Options with decreasing implied volatility: BPT WETF NFLX BMRN SNDK STX TSM MAT FAST INTC
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use